You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,196,244


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,196,244
Title:Method of transposon-mediated mutagenesis in the nematode caenorhabditis elegans
Abstract: The present invention provides methods for generating and identifying mutations in Caenorhabditis elegans. Disclosed herein are methods for introducing DNA into the C. elegans germline, methods for expressing DNA in the C. elegans germline, and methods for generating C. elegans mutants by using controlled mobilization of endogenous and heterologous transposons. Also disclosed are a transgene construct for expression in C. elegans and methods for inserting single copy DNA sequences into the C. elegans germline, and engineering mutations into the C. elegans genome.
Inventor(s): Bessereau; Jean-Louis (Paris, FR), Jorgensen; Erik M. (Salt Lake City, UT)
Assignee: University of Utah (Salt Lake City, UT)
Application Number:09/980,644
Patent Claims:1. A method of transposon-mediated mutagenesis in a C. elegans genome, comprising: a. introducing a transgene construct into the C. elegans genome, wherein the construct comprises a transposase gene which is operably linked to a regulable expression control element and a 3' untranslated region of a gene that is expressed in the C. elegans germline, wherein the 3' untranslated region comprises a glh-2 3' untranslated region; and b. expressing the transposase gene, such that a transposon in the C. elegans genome transposes, causing a mutation in the C. elegans germline.

2. The method of claim 1, wherein the transposon comprises a heterologous transposon.

3. The method of claim 2, wherein the heterologous transposon is introduced into the C. elegans genome.

4. The method of claim 2, wherein the transposon comprises a Mos 1 transposon.

5. The method of claim 2, wherein the transposase gene comprises restriction sites 5' of the start codon, restriction sites 5' of the stop codon, and an artificial intron in the transposase gene open reading frame.

6. The method of claim 2, wherein the regulable expression control element is an inducible promoter.

7. The method of claim 6, wherein the promoter comprises a heat-shock promoter.

8. The method of claim 6, wherein the promoter comprises a tetracycline-regulated promoter.

9. The method of claim 2, wherein the construct is substantially free of bacterial plasmid DNA sequences.

10. The method of claim 2, wherein the construct is substantially free of repeated DNA sequences.

11. The method of claim 2, wherein the regulable expression control element comprises a glh-2 promoter.

12. The method of claim 1, wherein the transposon comprises an endogenous transposon.

13. The method of claim 12, wherein the transposon comprises a Tc3 transposon.

14. The method of claim 13, wherein the transposase gene is a TC3A transposase gene.

15. The method of claim 12, wherein the regulable expression control element is an inducible promoter.

16. The method of claim 15, wherein the promoter comprises a heat-shock promoter.

17. The method of claim 15, wherein the promoter comprises a tetracycline-regulated promoter.

18. The method of claim 1, wherein the transposase gene is a TC3A transposase gene.

19. The method of claim 1, wherein the construct is substantially free of bacterial plasmid DNA sequences.

20. The method of claim 1, wherein the construct is substantially free of repeated DNA sequences.

21. The method of claim 1, wherein the regulable expression control element comprises a heat-shock promoter.

22. The method of claim 1, wherein the regulable expression control element comprises a glh-2 promoter.

23. The method of claim 1, further comprising introduction of one or more additional copies of an endogenous transposon into the C. elegans germline.

24. The method of claim 23, wherein the endogenous transposon is a Tc3 transposon.

Details for Patent 7,196,244

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2019-06-01
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2019-06-01
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2019-06-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.